Nurix Therapeutics (NRIX) Stock Forecast and Price Target (2026)
Last updated November 2026
Short answer
14 analysts covering Nurix Therapeutics (NRIX) carry an average price target of $33.50 as of November 2026, +160.7% against the $12.85 share price on November 20, 2026. The published targets run from $20.00 to $41.00, a spread of 63% of the average, so the disagreement is moderate. The rating split is 13 buy, 1 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market. Walnut is not an investment adviser.
NRIX analyst price targets
NRIX analyst data as of November 2026, sourced from Yahoo Finance and may be delayed. The price is the last one Yahoo Finance reported on November 20, 2026.A price target is what an analyst published on a date, not a forecast Walnut endorses, and targets are typically set on a 12-month view. Verify current figures before deciding.
The average target of $33.50 sits well above the $12.85 price, +160.7%. The median is $34.50, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.
What the NRIX target range actually tells you
The published targets span $20.00 to $41.00. That gap is 63% of the average target, which counts as moderate disagreement. A spread like this is fairly typical: enough agreement that the average means something, enough disagreement that it should not be treated as precise.
The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the NRIX is it a buy page.
Recent analyst actions on NRIX
| Firm | Action | Target | Prior | Date |
|---|---|---|---|---|
| Wells Fargo | Lowered (Equal-Weight) | $20.00 | $25.00 | November 4, 2026 |
| HC Wainwright & Co. | Raised (Buy) | $36.00 | $34.00 | October 16, 2026 |
| RBC Capital | Lowered (Outperform) | $35.00 | $36.00 | October 13, 2026 |
| Oppenheimer | Raised (Outperform) | $32.00 | $28.00 | October 13, 2026 |
| Truist Securities | Lowered (Buy) | $33.00 | $34.00 | October 13, 2026 |
| Baird | Raised (Outperform) | $36.00 | $33.00 | October 13, 2026 |
| Needham | Maintained (Buy) | $34.00 | $34.00 | October 13, 2026 |
| RBC Capital | Raised (Outperform) | $36.00 | $33.00 | August 10, 2026 |
| Morgan Stanley | Raised (Overweight) | $38.00 | $36.00 | July 28, 2026 |
| UBS | Raised (Buy) | $31.00 | $23.00 | July 22, 2026 |
| Mizuho | Raised (Outperform) | $34.00 | $30.00 | July 13, 2026 |
The most recent published rating actions on NRIX within the last six months, from Yahoo Finance. Each row is dated because a target only means something alongside the date it was set. Walnut is not an investment adviser and does not endorse any of these views.
In the last six months there have been 7 raises and 3 cuts among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving.
How analysts rate NRIX
Of the analysts with a published rating, 13 say buy, 1 say hold, and 0 say sell, so 93% carry a buy. That mix has been broadly steady over the last three months.
The distribution says more than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.
Why a NRIX price target is not a prediction
- It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
- The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
- Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
- Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.
NRIX earnings and revenue forecast
For the fiscal year ending Nov 2026, the 4 analysts publishing estimates on NRIX expect earnings of $3.02 per share and revenue of $744.8 million (+787%).
| Period | EPS estimate | EPS growth | Revenue estimate | Revenue growth |
|---|---|---|---|---|
Quarter ending Nov 2026 next quarter to report, 3 analysts | $1.51 -$0.64 to $5.26 | n/a | $287.9 million $65.8 million to $701 million | +2020% |
Quarter ending Feb 2027 the quarter after, 1 analyst | -$0.59 | n/a | $15 million | +140% |
Fiscal year ending Nov 2026 fiscal year next to report, 4 analysts | $3.02 $2.96 to $3.10 | n/a | $744.8 million $704 million to $785.2 million | +787% |
Fiscal year ending Nov 2027 the fiscal year after, 4 analysts | -$1.28 -$2.48 to -$0.62 | n/a | $123.2 million $58 million to $200 million | -83% |
Consensus estimates for NRIX published by sell-side analysts, as of November 2026, from Yahoo Finance. Each figure is the average of the analysts counted, with the lowest and highest estimate beneath it; growth compares with the same period a year earlier and is left blank where either figure is a loss. Estimates change constantly. Walnut is not an investment adviser.
Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Nurix Therapeutics next reports around January 28, 2027 (an estimated date), which is when these figures get tested against actual results.
Is there a 2030 forecast for NRIX?
Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering NRIX do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.
What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.
For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Nurix Therapeutics can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.
What could move NRIX from here
In short: the drivers cited most often are Bexobrutideg registrational path, Roche collaboration, Partnered pipeline and platform. The risk cited most often against it is as a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.28 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the NRIX is it a buy page.
Your questions about Nurix Therapeutics
Ask Walnut's AI anything about NRIX and see how it fits what you own.
FAQ
What is the price target for Nurix Therapeutics (NRIX)?
+
The average analyst price target for NRIX is $33.50 as of November 2026, across 14 analysts. The average is +160.7% against the $12.85 share price on November 20, 2026, so the consensus sits well above where the stock trades. The median target, which is less distorted by one extreme view, is $34.50. Targets move constantly; verify the current figure before relying on it.
How high could NRIX go?
+
The highest published target is $41.00, which is +219.1% against the $12.85 price. It is one analyst's most optimistic case, not a ceiling and not a forecast. The lowest is $20.00. The gap between them answers this question best: analysts who all follow Nurix Therapeutics closely disagree by 63% of the average target, so treat any single number as one scenario.
How many analysts cover NRIX?
+
14 analysts publish estimates on NRIX as of November 2026. Of those with a published rating, 13 say buy, 1 hold, and 0 sell, so 93% carry a buy rating. More coverage usually means the consensus is better informed, though it also means the obvious points are already in the price.
Are analyst price targets for NRIX accurate?
+
Treat them as informed opinion, not measurement. Two things matter here. Sell-side ratings skew positive across the market, and NRIX is no exception at 93% buy ratings, so the distribution is not a balanced vote. And targets tend to follow the share price at least as often as they lead it, getting raised after a stock has already run. They are most useful as a read on what the informed consensus expects, and least useful as a prediction of where the price lands.
Has the NRIX price target been raised or cut recently?
+
In the last six months there have been 7 raises and 3 cuts among the published actions on NRIX. The most recent was Wells Fargo, which lowered its target to $20.00 from $25.00 on November 4, 2026. The direction of revisions often tells you more than the level, because it shows which way the informed view is moving.
What are analysts' earnings estimates for Nurix Therapeutics (NRIX)?
+
For the fiscal year ending Nov 2026, the 4 analysts publishing estimates on NRIX expect earnings of $3.02 per share and revenue of $744.8 million (+787%). For the fiscal year ending Nov 2027, the consensus is -$1.28 per share. These are consensus estimates as of November 2026, the average of what the covering analysts publish, and they are revised constantly, especially around each earnings report. They describe expectations, not results.
When does NRIX report earnings next?
+
Nurix Therapeutics's next earnings report is expected around January 28, 2027, a date estimated from its reporting history that the company has not yet confirmed. The report is when the estimates on this page get tested against actual results, which is why targets and estimates tend to move most in the days after it.
What is the NRIX stock price prediction for 2030?
+
There is no published one. Analyst targets run to about twelve months and no firm covering NRIX publishes a 2030 figure, so any site showing one has extrapolated a growth rate of its own. The answerable version of the question is what the current price already assumes about Nurix Therapeutics's earnings, which the forward multiple on this page sets out, and what would have to change for that to break.
Will NRIX go up in 2026?
+
Nobody knows, including the analysts publishing targets. What the numbers on this page tell you is where informed opinion currently sits and how much it disagrees with itself, which is useful and different from a prediction. The risk most often cited against Nurix Therapeutics: As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.28 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials. Walnut is not an investment adviser.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.